Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
- Conditions
- Myelodysplastic Syndrome
- Registration Number
- NCT00043381
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Brief Summary
To compare the safety and efficacy profiles of decitabine to those of supportive care in adults with advanced-stage myelodysplastic syndrome (MDS)
- Detailed Description
This experimental (investigational) study is intended to answer the question of whether decitabine is any better than supportive care alone in delaying progression (worsening) of the disease, prolonging survival or improving the overall quality of life for MDS patients who are not candidates for bone marrow transplant (BMT).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (24)
Alta Bates Comprehensive Cancer Center
🇺🇸Berkeley, California, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
Scripps Clinic
🇺🇸Escondido, California, United States
Loma Linda Univ. Cancer Center
🇺🇸Loma Linda, California, United States
Univ. California San Francisco Medical School
🇺🇸San Francisco, California, United States
University of Florida
🇺🇸Gainesville, Florida, United States
H. Lee Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
James A. Haley Veteran's Hospital
🇺🇸Tampa, Florida, United States
Rush Medical Center
🇺🇸Chicago, Illinois, United States
University of Illinois at Chicago
🇺🇸Chicago, Illinois, United States
Scroll for more (14 remaining)Alta Bates Comprehensive Cancer Center🇺🇸Berkeley, California, United States